<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613209</url>
  </required_header>
  <id_info>
    <org_study_id>Sevicontrol-1</org_study_id>
    <nct_id>NCT01613209</nct_id>
  </id_info>
  <brief_title>Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine</brief_title>
  <acronym>Sevicontrol1</acronym>
  <official_title>Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan 40 mg / Amlodipine 10 mg in Patients With Insufficiently Controlled Hypertension Under Monotherapy With Candesartan 32 mg - an Open Phase IIIb Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to find out whether a recently introduced combination of two blood
      pressure lowering agents (olmesartan and amlodipine) has a different blood pressure lowering
      effect than a single active substance. In addition the investigators want to find out whether
      there is a difference in the changes in blood pressure over the course of a day depending on
      the time when the medications are taken (in the morning or at night). Male and female
      patients over 18 years of age may participate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigation of changes in blood pressure after six weeks therapy with a fixed combination
      of 40 mg olmesartan and 10 mg amlodipine compared to a monotherapy with 32 mg candesartan.
      Investigation of changes in dipping-profile after a further six weeks of therapy with the
      fixed combination when time of intake is switched from morning to evening.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ABPM (ambulatory blood pressure measurement) mean daytime systolic values and change in systolic OBPM (office blood pressure measurement).</measure>
    <time_frame>after six and after 12 weeks</time_frame>
    <description>After 6 weeks therapy with a fixed combination of olmesartan and amlodipine compared to monotherapy with candesartan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in systolic OBPM</measure>
    <time_frame>after 6 and after 12 weeks</time_frame>
    <description>After 6 weeks therapy with a fixed combination of olmesartan and amlodipine compared to monotherapy with candesartan: change in systolic OPM.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in diastolic OBPM</measure>
    <time_frame>after six and after 12 weeks</time_frame>
    <description>After 6 weeks therapy with a fixed combination of olmesartan and amlodipine compared to monotherapy with candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic and diastolic ABPM night mean values</measure>
    <time_frame>after 6 weeks therapy with fixed combination of olmesartan and amlodipine</time_frame>
    <description>first ABPM to be performed after 2 weeks wash-out followed by six weeks monotherapy with candesartan. Second ABPM to be performed after six weeks therapy with the fixed combination, given in the morning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in 24 hr mean values and diastolic day mean value</measure>
    <time_frame>after six and after 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of patients over the four dipper types</measure>
    <time_frame>after six and after 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients achieving target values for OBPM and ABPM</measure>
    <time_frame>after six and after 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>From screening visit to end of follow-up, up to 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Olmesartan/Amlodipin fixed combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan cilexetil</intervention_name>
    <description>candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,</description>
    <arm_group_label>Olmesartan/Amlodipin fixed combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan/Amlodipin</intervention_name>
    <description>olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)</description>
    <arm_group_label>Olmesartan/Amlodipin fixed combination</arm_group_label>
    <other_name>Sevikar(r)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  essential hypertension, i. e. systolic OPM &gt;=140 mmHg at screening and &gt;=160 mmHg
             after two weeks wash-out

        Exclusion Criteria:

          -  systolic office bp &gt; 180 mm Hg at screening visit

               -  known hypertensive retinopathy GIII or IV

               -  recent (&lt; 4 weeks ago) myocardial infarction or indication for coronary or
                  peripheral revascularisation

               -  type I diabetes or poorly controlled (HbA1c &gt;= 8) type II diabetes

               -  chronic heart failure NYHA III or IV

               -  prior stroke or TIA

               -  creatinine clearance &lt; 60 ml/min or condition after kidney transplant

               -  moderately or severely impaired liver function (ALT or AST or bilirubin more than
                  double normal value)

               -  women of childbearing potential without highly effective contraception, pregnant
                  or breastfeeding women

               -  concomitant therapy with lithium

               -  hemodynamically relevant mitral or aortic valve stenosis (&gt;= II°) or hypertrophic
                  obstructive cardiomyopathy

               -  concomitant therapy with strong CYP3A4 inhibitors or inductors

               -  african patients

               -  concomitant severe psychiatric condition that might impair proper intake of study
                  medication

               -  life expectancy &lt; 6 months

               -  night shift workers

               -  known other mandatory indication for treatment with antihypertensive medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Lueders, Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus St.-Josef-Stift, Krankenhausstraße 13, D-49661 Cloppenburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Praxis Dr. Loddo</name>
      <address>
        <city>Rastede</city>
        <state>Niedersachsen</state>
        <zip>26180</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Paschmionka</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04316</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Reimer</name>
      <address>
        <city>Anderbeck</city>
        <zip>38836</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Heinz</name>
      <address>
        <city>Bergisch-Gladbach</city>
        <zip>51429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Zemmrich</name>
      <address>
        <city>Berlin</city>
        <zip>12043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Biedermann</name>
      <address>
        <city>Blankenhain</city>
        <zip>99444</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Josefs-Hospital</name>
      <address>
        <city>Cloppenburg</city>
        <zip>49661</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Pohl</name>
      <address>
        <city>Dresden</city>
        <zip>01129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Koßler-Wiesweg</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Rövenich</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Strzata</name>
      <address>
        <city>Kapellendorf</city>
        <zip>99510</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Pitule</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://dx.doi.org/10.1111/jch.12202</url>
    <description>Results Publication</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>ABPM</keyword>
  <keyword>office blood pressure</keyword>
  <keyword>olmesartan</keyword>
  <keyword>amlodipine</keyword>
  <keyword>fixed combination</keyword>
  <keyword>time of intake</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

